TherapeuticsMD Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

TherapeuticsMD şirketinin kazançları yıllık ortalama -10.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 12.9% oranında artan oldu. Gelirler yıllık ortalama 39.1% oranında artan oldu.

Anahtar bilgiler

-10.2%

Kazanç büyüme oranı

1.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	39.1%
Özkaynak getirisi	n/a
Net Marj	-29.5%
Son Kazanç Güncellemesi	30 Jun 2022

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

TherapeuticsMD nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:29TA Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 22	92	-27	174	6
31 Mar 22	86	-182	185	6
31 Dec 21	87	-172	188	7
30 Sep 21	91	-172	201	8
30 Jun 21	85	-157	182	8
31 Mar 21	72	-166	178	9
31 Dec 20	65	-184	193	10
30 Sep 20	58	-191	198	12
30 Jun 20	63	-190	204	15
31 Mar 20	58	-193	196	17
31 Dec 19	50	-176	175	20
30 Sep 19	39	-166	157	22
30 Jun 19	19	-170	142	25
31 Mar 19	16	-148	130	27
31 Dec 18	16	-133	116	27
30 Sep 18	15	-115	95	32
30 Jun 18	16	-94	76	31
31 Mar 18	17	-80	62	33
31 Dec 17	17	-77	58	34
30 Sep 17	17	-78	60	33
30 Jun 17	18	-89	63	41
31 Mar 17	18	-90	59	47
31 Dec 16	19	-90	51	54
30 Sep 16	20	-85	44	57
30 Jun 16	20	-79	36	59
31 Mar 16	21	-85	32	69
31 Dec 15	20	-85	29	72

Kaliteli Kazançlar: 29TA şu anda kârlı değil.

Büyüyen Kar Marjı: 29TA şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 29TA kârlı değildir ve zararlar son 5 yılda yılda 10.2% oranında artmıştır.

Büyüme Hızlandırma: 29TA 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 29TA kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 28.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 29TA 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

TherapeuticsMD Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

First quarter 2022 earnings released: US$5.69 loss per share (vs US$5.67 loss in 1Q 2021)

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Recent updates

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

First quarter 2022 earnings released: US$5.69 loss per share (vs US$5.67 loss in 1Q 2021)

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought €510k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought €619k worth of stock

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

Revenue beats expectations

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high: €1.31

TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health

New 90-day low: €0.94

New 90-day low: €1.03

Revenue beats expectations

Third quarter 2020 earnings released: US$0.12 loss per share

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

New 90-day low: €1.06

TherapeuticsMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Knight Therapeutics Inc and TherapeuticsMD, Inc. Announce Health Canada Approval of BIJUVA

First half earnings released

TherapeuticsMD, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - €1.92

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from S&P Pharmaceuticals Select Industry Index

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin